BTG unit pleads guilty in U.S. to misbranding, to pay $36 mln

Nov 7 (Reuters) - A U.S. unit of British drug company BTG

Plc pleaded guilty on Monday to a misdemeanor related to

its misbranding of the embolic device LC Bead, and will pay

about $36 million to resolve its criminal and civil liability,

the U.S. Department of Justice said.

Read more